Q1 EPS Estimate for Edwards Lifesciences Reduced by Analyst

Edwards Lifesciences Co. (NYSE:EW) – Analysts at Zacks Research dropped their Q1 2025 earnings per share estimates for shares of Edwards Lifesciences in a research note issued to investors on Wednesday, November 20th. Zacks Research analyst R. Department now forecasts that the medical research company will post earnings per share of $0.58 for the quarter, down from their prior estimate of $0.59. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.57 per share. Zacks Research also issued estimates for Edwards Lifesciences’ Q2 2025 earnings at $0.61 EPS, FY2025 earnings at $2.42 EPS, Q1 2026 earnings at $0.66 EPS, Q2 2026 earnings at $0.69 EPS and FY2026 earnings at $2.78 EPS.

Other analysts have also recently issued research reports about the company. Evercore ISI decreased their target price on Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating for the company in a report on Tuesday, October 1st. Jefferies Financial Group downgraded shares of Edwards Lifesciences from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $85.00 to $70.00 in a research note on Wednesday, September 18th. Barclays cut their target price on shares of Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating on the stock in a research note on Monday, September 9th. Royal Bank of Canada reduced their target price on shares of Edwards Lifesciences from $85.00 to $75.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. Finally, Truist Financial cut their price objective on Edwards Lifesciences from $71.00 to $70.00 and set a “hold” rating on the stock in a research report on Friday, October 25th. Seventeen analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Edwards Lifesciences has an average rating of “Hold” and a consensus price target of $75.67.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $70.48 on Friday. Edwards Lifesciences has a one year low of $58.93 and a one year high of $96.12. The company has a 50 day moving average price of $67.70 and a 200 day moving average price of $75.66. The firm has a market capitalization of $41.57 billion, a price-to-earnings ratio of 10.17, a price-to-earnings-growth ratio of 3.96 and a beta of 1.12. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, meeting the consensus estimate of $0.67. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The firm had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.57 billion. During the same period in the prior year, the firm posted $0.59 earnings per share. The business’s quarterly revenue was up 8.9% compared to the same quarter last year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Crewe Advisors LLC acquired a new stake in Edwards Lifesciences during the first quarter valued at approximately $28,000. First Community Trust NA acquired a new stake in shares of Edwards Lifesciences during the second quarter valued at approximately $29,000. Webster Bank N. A. purchased a new stake in shares of Edwards Lifesciences in the 2nd quarter valued at approximately $39,000. FSA Wealth Management LLC acquired a new position in Edwards Lifesciences in the 3rd quarter worth approximately $30,000. Finally, Versant Capital Management Inc grew its position in Edwards Lifesciences by 206.3% during the 2nd quarter. Versant Capital Management Inc now owns 484 shares of the medical research company’s stock worth $45,000 after purchasing an additional 326 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $69.51, for a total value of $347,550.00. Following the completion of the transaction, the vice president now owns 46,936 shares in the company, valued at approximately $3,262,521.36. This represents a 9.63 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Larry L. Wood sold 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total value of $1,647,750.00. Following the transaction, the insider now owns 198,526 shares of the company’s stock, valued at approximately $13,084,848.66. This represents a 11.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 40,000 shares of company stock valued at $2,657,000. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.